EMA grants Rexgenero's Lead Product REX-001 Advanced Therapy Medicinal Product Certificate for Manufacturing Quality and Non-clinical Data

Tuesday, January 30, 2018 Clinical Trials News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, January 30, 2018 /PRNewswire/ --

REX-001 is a novel cell therapy for the treatment of

Critical Limb Ischemia (CLI), a disease which affects an estimated one million people in Europe

Rexgenero Ltd, a clinical-stage regenerative

medicine company developing advanced cell-based therapies with a focus on Critical Limb Ischemia (CLI), today announces that the European Medicines Agency (EMA) has granted Rexgenero an Advanced Therapy Medicinal Product (ATMP) certificate for manufacturing quality and non-clinical data. The EMA certification paves the way for the Marketing Authorization Application (MAA) of its lead product REX-001, a novel cell therapy currently in a Phase III programme for the treatment of Critical Limb Ischemia (CLI).

Joe Dupere, Rexgenero's CEO, commented, "We are delighted to have been granted an ATMP certificate for manufacturing quality and non-clinical data for REX-001. This is a major milestone for us as we work to bring this novel cell therapy to patients diagnosed with CLI, a disease with high unmet medical needs. We believe that REX-001 has the potential to be one of the first effective cell therapy products available for patients with CLI, a disease strongly associated with a high risk of amputation and mortality."

Rexgenero received the certificate following a thorough scientific evaluation of the manufacturing quality data and non-clinical data by the EMA's Committee for Advanced Therapies (CAT).

About Rexgenero 

Rexgenero is a clinical-stage regenerative medicine company developing innovative cell-based therapies targeting serious diseases with unmet medical needs.

The Company's lead candidate REX-001 is a highly innovative autologous cell therapy that is being studied in a Phase III clinical programme in patients with Critical Limb Ischemia (CLI) with diabetes, a poorly treated disease with a high risk of amputation and death. REX-001 has been shown to be effective in Phase I/II and Phase II trials, alleviating CLI in the majority of patients, offering the potential to increase the quality of life of CLI patients by reducing pain, alleviating ulcers, increasing mobility, improving sleep and reducing the need for amputation. Rexgenero is developing REX-001 in a range of indications and, pending approval, intends to launch and market this specialty product in major territories.

Rexgenero is a privately-owned company, which draws on an exceptional understanding of the fundamental science of cell therapies developed by the Andalusian Health Authority (Servicio Andaluz de Salud) and Andalusian Initiative of Advanced Therapies.

The Company was founded in 2015 and is headquartered in London (UK) with R&D and manufacturing operations in Seville (Spain).

For more information, please visit www.rexgenero.com


Rexgenero Joe Dupere, CEO T: +44-(0)-203-709-1969 E: info@rexgenero.com

Citigate Dewe Rogerson Sylvie Berrebi, Shabnam Bashir T: +44-(0)-20-7638-9571 E: rexgenero@citigatedewerogerson.com

SOURCE Rexgenero

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store